1428243-25-7

Basic information

• Product Name: (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt
• Synonyms: (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt
• CAS NO: 1428243-25-7
• Molecular Weight: 448.562
• Mol File: 1428243-25-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt(1428243-25-7)
• EPA Substance Registry System: (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt(1428243-25-7)

Safety Data

• Hazardous Substances Data: 1428243-25-7(Hazardous Substances Data)

Usage

Uses

(E/Z)-9-Hydroxy-5,9-dimethyldec-4-enal acts as a reagent in the preparation of imidazopyrrolopyrazine derivatives and analogs for use as protein kinase modulators.

Upstream product

• 10420-89-0 (S)-1-(1-Naphthyl)ethylamine 
• 3886-70-2 (R)-1-(1-Naphthyl)ethylamine 
• 27805-84-1 (cis)-2-pentenoic acid ethyl ester 
• 55314-57-3 ethyl pent-2-ynoate 
• 2445-93-4 ethyl 2-pentenoate 

Downstream Products

• 1428243-26-8 (3R,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate 
• 1428243-27-9 (3R,4S)-benzyl 3-(2-(tert-butoxycarbonyl(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)amino)acetyl)-4-ethylpyrrolidine-1-carboxylate 
• 1310726-60-3 (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide 

Relevant articles and documents

Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib

Process development of a six-stage synthesis of upadacitinib, a JAK1 inhibitor, is described. It is highlighted by an enantioselective and diastereoselective hydrogenation of a tetrasubstituted olefin to set the two pyrrolidine stereocenters. Preparation of the main fragments and strategies to link them together, optimization of the imidazole cyclization, and in-depth understanding of the formation of the urea moiety at the final stage are discussed.

NOVEL TRICYCLIC COMPOUNDS

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.